| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/02/2004 | CA2516453A1 Composition and methods for inhibiting cell survival |
| 09/02/2004 | CA2516452A1 Estradiol metabolites for the treatment of pulmonary hypertension |
| 09/02/2004 | CA2516450A1 Method to treat chronic heart failure and/or elevated cholesterol levels |
| 09/02/2004 | CA2516393A1 Synthesis of peloruside a and analogs thereof for use as antitumor agents |
| 09/02/2004 | CA2516328A1 Inhibitors of hepatitis c virus, compositions and treatments using the same |
| 09/02/2004 | CA2516304A1 Combination therapy for treating protein deficiencies |
| 09/02/2004 | CA2516266A1 Methods involving pde4, compositions, and the screening thereof, for the treatment of degenerative ocular pathologies |
| 09/02/2004 | CA2516250A1 A1 adenosine receptor antagonists |
| 09/02/2004 | CA2516235A1 Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatments using the same |
| 09/02/2004 | CA2516234A1 N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
| 09/02/2004 | CA2516185A1 Antitumoral 18a-homoestra-1,3,5(10)-trien-3-yl 2-substituted sulfamates |
| 09/02/2004 | CA2516184A1 Antitumoral d-homoestra-1, 3, 5 (10)-trien-3-yl 2-substituted sulfamates |
| 09/02/2004 | CA2516177A1 2-substituted estra-1,3,5(10)-triene-3-yl sulfamate with an anti-tumour action |
| 09/02/2004 | CA2516097A1 A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent |
| 09/02/2004 | CA2516021A1 6-substituted imidazopyrazines |
| 09/02/2004 | CA2515984A1 Antibacterial indolone oxazolidinones, intermediates for their preparation and pharmaceutical compositions containing them |
| 09/02/2004 | CA2515971A1 Nitrate esters of phenylaminothiophenacetic acid derivatives |
| 09/02/2004 | CA2515939A1 Novel compounds |
| 09/02/2004 | CA2515929A1 Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions |
| 09/02/2004 | CA2515889A1 The selective and specific preparation of discrete peg compounds |
| 09/02/2004 | CA2515887A1 Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier |
| 09/02/2004 | CA2515777A1 Biphenyl derivatives |
| 09/02/2004 | CA2515679A1 Glycinamide derivative for inhibiting hiv replication |
| 09/02/2004 | CA2515567A1 Pharmaceutical combinations comprising a nos inhibitor and an nmda receptor antagonist |
| 09/02/2004 | CA2515480A1 Use of acylated aminopropanediols and sulphur and nitrogen analogues of same for different therapeutic applications |
| 09/02/2004 | CA2515434A1 Adamantane derivatives, processes for their preparation and pharmaceutical composition containing them |
| 09/02/2004 | CA2515251A1 Blood-vessel-growth promoter |
| 09/02/2004 | CA2514892A1 Compositions comprising a defined polysaccharide component |
| 09/02/2004 | CA2514889A1 Compositions comprising a polysaccharide component and one or more coating layers |
| 09/02/2004 | CA2514875A1 Rapid absorption selective 5-ht agonist formulations |
| 09/02/2004 | CA2514870A1 Compositions comprising a plurality of particles or agglomerates having a defined particle size |
| 09/02/2004 | CA2514862A1 Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 09/02/2004 | CA2514804A1 Compositions containing creatine, creatinine and a methyl xanthine |
| 09/02/2004 | CA2514061A1 Combination therapy for the treatment of immunoinflammatory disorders |
| 09/02/2004 | CA2513123A1 Hiv inhibiting 1,2,4-triazines |
| 09/02/2004 | CA2512883A1 Sulfonamide derivatives as ppar modulators |
| 09/02/2004 | CA2493475A1 Method for treating severe heart failure and medicament therefor |
| 09/02/2004 | CA2478473A1 Aldosterone blocker therapy to prevent or treat inflammation-related disorders |
| 09/01/2004 | EP1452868A2 Method for selecting a candidate drug compound |
| 09/01/2004 | EP1452600A1 Receptor and nucleic acid molecule encoding said receptor |
| 09/01/2004 | EP1452584A1 Method for recovering recyclable material from dregs and use thereof |
| 09/01/2004 | EP1452583A1 New brewing process, beer brewed thereby and use thereof |
| 09/01/2004 | EP1452546A2 Poly-beta-1,4-N-Acetyglucosamine |
| 09/01/2004 | EP1452545A1 Novel chitosans |
| 09/01/2004 | EP1452534A1 Pleuromutlin derivatives as antimicrobials |
| 09/01/2004 | EP1452530A1 Azole compound and medicinal use thereof |
| 09/01/2004 | EP1452527A1 Azabicyclo compound, matrix metalloprotease inhibitor, and skin preparation |
| 09/01/2004 | EP1452526A1 Indole compound and medicinal use thereof |
| 09/01/2004 | EP1452525A1 Amide derivatives and drugs |
| 09/01/2004 | EP1452524A1 "2-oxo-1-pyrrolidine derivative and its pharmaceutical uses" |
| 09/01/2004 | EP1452522A2 Novel compounds and compositions as protease inhibitors |
| 09/01/2004 | EP1452521A1 Cyclic compound and ppar agonist |
| 09/01/2004 | EP1452181A1 Regulation of immune responses by manipulation of intermediary metabolite levels |
| 09/01/2004 | EP1452180A1 Stanol composition and the use thereof |
| 09/01/2004 | EP1452179A1 Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
| 09/01/2004 | EP1452178A1 Persistent filmy preparation for topical administration containing prostaglandin derivative |
| 09/01/2004 | EP1452177A1 Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent |
| 09/01/2004 | EP1452176A1 Insulin resistance improving agents |
| 09/01/2004 | EP1452175A1 Manganese based organometallic complexes, pharmaceutical compositions and dietetic products |
| 09/01/2004 | EP1452174A1 METHOD OF STABILIZING REDUCED COENZYME Q sb 10 /sb |
| 09/01/2004 | EP1452172A2 Multiple unit pharmaceutical preparation |
| 09/01/2004 | EP1452169A1 Aqueous base liquid pharmaceutical compositions in suspension form for the oral administration of ibuprofen |
| 09/01/2004 | EP1452096A1 Method of fattening poultry |
| 09/01/2004 | EP1451856A2 Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells |
| 09/01/2004 | EP1451590A2 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases |
| 09/01/2004 | EP1451577A2 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases |
| 09/01/2004 | EP1451572A2 Multi-disciplinary approach to validating or identifying targets using an in vivo system |
| 09/01/2004 | EP1451369A2 Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201 |
| 09/01/2004 | EP1451364A2 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| 09/01/2004 | EP1451324A2 G-protein coupled receptor lustr2 and uses thereof |
| 09/01/2004 | EP1451323A2 Pharmaceutical compositions of marine sponge microciona prolifera |
| 09/01/2004 | EP1451308A2 Therapeutic use of aziridino compounds |
| 09/01/2004 | EP1451307A2 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/01/2004 | EP1451294A2 Nutrient medium for maintaining neural cells in injured nervous system |
| 09/01/2004 | EP1451227A2 Method for controlling angiogenesis in animals |
| 09/01/2004 | EP1451225A1 Agonists of recombinant human histamine h3 receptor |
| 09/01/2004 | EP1451222A2 Novel proteins with il-6 inhibiting activity |
| 09/01/2004 | EP1451205A2 Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer |
| 09/01/2004 | EP1451203A1 3-beta-d-ribofuranosylthiazolo(4,5-delta)pyridimine nucleosides and uses thereof |
| 09/01/2004 | EP1451202A1 Aryl fused azapolycyclic compounds |
| 09/01/2004 | EP1451197A1 4-(oxazolopyridin-2-yl)-1,4-diazabicyclo- 3.2.2 nonane derivatives, preparation and therapeutic use thereof |
| 09/01/2004 | EP1451196A1 The use of anti-histaminics for acute reduction of elevated intracranial pressure |
| 09/01/2004 | EP1451194A2 Preparation of levofloxacin and forms thereof |
| 09/01/2004 | EP1451193A1 Podophyllotoxins as antiproliferative agents |
| 09/01/2004 | EP1451192A1 Novel crystalline compound |
| 09/01/2004 | EP1451191A1 Thioether substituted imidazoquinolines |
| 09/01/2004 | EP1451190A1 Triazolo(4,3-a)pyrido(2,3-d)pyrimidin-5-one derivatives, compositions containing same, preparation method and use thereof |
| 09/01/2004 | EP1451189A1 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo- 3.2.2]nonane derivatives, preparation and therapeutic use thereof |
| 09/01/2004 | EP1451188A1 4-(oxadiazol-3-yl)-1,4-diazabicyclo 3.2.2]-nonane derivatives, preparation and therapeutic use thereof |
| 09/01/2004 | EP1451187A1 Amide substituted imidazopyridines |
| 09/01/2004 | EP1451186A2 Urea substituted imidazopyridines |
| 09/01/2004 | EP1451185A1 Indole-2-carboxamides as factor xa inhibitors |
| 09/01/2004 | EP1451184A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451183A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451182A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451181A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1451177A1 Substituted 2-pyrrolidine-2-yl-1h-indole derivatives for the treatment of migraine |
| 09/01/2004 | EP1451176A2 Benzazepine derivatives and their use as 5-ht ligands |
| 09/01/2004 | EP1451175A1 Thrombin inhibitors |
| 09/01/2004 | EP1451174A2 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers |